SWOG clinical trial number
SWOG-9343
Evaluation of Combined Androgen Suppression and Fixed Schedule Suramin in Patients with Newly Diagnosed Metastatic Prostate Cancer, Phase II
Closed
Phase
Accrual
100%
Published
Abbreviated Title
Advanced Prostate
Activated
08/15/1994
Closed
01/15/1997
Research committees
Genitourinary Cancer
Publication Information Expand/Collapse
2000
Androgen deprivation and four courses fixed-schedule suramin treatment in patients with newly diagnosed metastatic prostate cancer: a Southwest Oncology Group study
1998
Androgen deprivation (AD) + 4-courses of fixed-schedule suramin in D2 prostate cancer (PCA) patients (pts): A Southwest Oncology Group phase II study.
Analysis of suramin (S) levels obtained from D2 hormone naive prostate cancer (HNPCA) patients (pts) treated with fixed bolus suramin: A Southwest Oncology Group study.
Other Clinical Trials
SWOG Clinical Trial Number
S2210
S2210, "Targeted Neoadjuvant Treatment for Patients with Localized Prostate Cancer and Germline DNA Repair Deficiency"
Research Committee(s)
Genitourinary Cancer
Activated
08/14/2023
Accrual
2%
Open
Phase
SWOG Clinical Trial Number
S2200
S2200, A Phase II Randomized Trial of Cabozantinib with or Without Atezolizumab in Patients with Advanced Papillary Renal Cell Carcinoma: PAPMET2
Research Committee(s)
Genitourinary Cancer
Activated
09/19/2022
Accrual
10%
Open
Phase
SWOG Clinical Trial Number
CTSU/A031901
Duration of Immune Checkpoint Therapy in Locally Advanced or Metastatic Urothelial Carcinoma: A Randomized Phase 3 Non-Inferiority Trial
Research Committee(s)
Genitourinary Cancer
Activated
05/01/2021
Open
Phase